This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vlahovic, G. Articles by Crawford, J. Search for Related Content PubMed PubMed Citation Articles by Vlahovic, G. Articles by Crawford, J.

Activation of Tyrosine Kinases in Cancer

Duke University Medical Center, Division of Hematology/Oncology, Durham, North Carolina, USA

Correspondence: Jeffrey Crawford, M.D., Duke University Medical Center, Box 3198, Morris Building, Room 25178, Durham, North Carolina 27710, USA. Telephone: 919-684-5195; Fax: 919-681-5864; e-mail: crawf006{at}mc.duke.edu

Receptor and nonreceptor tyrosine kinases (TKs) have emerged as clinically useful drug target molecules for treating certain types of cancer. Epidermal growth factor receptor (EGFR)-TK is a transmembrane receptor TK that is overexpressed or aberrantly activated in the most common solid tumors, including non-small cell lung cancer and cancers of the breast, prostate, and colon. Activation of the EGFR-TK enzyme results in autophosphorylation, which drives signal transduction pathways leading to tumor growth and malignant progression. Randomized clinical trials of the EGFR-TK inhibitor gefitinib have demonstrated clinical benefits in patients with advanced non-small cell lung cancer whose disease had previously progressed on platinum- and docetaxel-based chemotherapy regimens. Bcr-Abl is a constitutively activated nonreceptor TK enzyme found in the cytoplasm of Philadelphia chromosome-positive leukemia cells. STI571 (imatinib mesylate) inhibits the Bcr-Abl TK, blocks the growth of these leukemia cells, and induces apoptosis. STI571 also inhibits other TKs, including the receptor TK c-kit, which is expressed in gastrointestinal stromal tumors. As TK inhibitors become available for clinical use, new challenges include predicting which patients are most likely to respond to these targeted TK inhibitors. Additional clinical trials are needed to develop the full potential of receptor and nonreceptor TK inhibitors for cancer treatment.

Key Words. Tyrosine kinase • Cancer • Epidermal growth factor receptor-tyrosine kinase • Bcr-Abl • Gefitinib • STI571

This article has been cited by other articles:

				N. VALERI, C. M. CROCE, and M. FABBRI Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer Cancer Genomics Proteomics, July 1, 2009; 6(4): 195 - 204. [Abstract] [Full Text] [PDF]

				B. Nagar c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571) J. Nutr., June 1, 2007; 137(6): 1518S - 1523S. [Abstract] [Full Text] [PDF]

				I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344. [Abstract] [Full Text] [PDF]

				J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]

				F. J. Delfino, H. Stevenson, and T. E. Smithgall A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer J. Biol. Chem., March 31, 2006; 281(13): 8829 - 8835. [Abstract] [Full Text] [PDF]

				N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]

				R. S. Benjamin, C. D. Blanke, J.-Y. Blay, S. Bonvalot, and B. Eisenberg Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies Oncologist, January 1, 2006; 11(1): 9 - 20. [Abstract] [Full Text] [PDF]

				C. Cutcliffe, D. Kersey, C.-C. Huang, Y. Zeng, D. Walterhouse, E. J. Perlman, and for the Renal Tumor Committee of the Children's On Clear Cell Sarcoma of the Kidney: Up-regulation of Neural Markers with Activation of the Sonic Hedgehog and Akt Pathways Clin. Cancer Res., November 15, 2005; 11(22): 7986 - 7994. [Abstract] [Full Text] [PDF]

				A. Shrivastava, M.A. von Wronski, A.K. Sato, D.T. Dransfield, D. Sexton, N. Bogdan, R. Pillai, P. Nanjappan, B. Song, E. Marinelli, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases Protein Eng. Des. Sel., September 1, 2005; 18(9): 417 - 424. [Abstract] [Full Text] [PDF]

				L. Yang, C. Lin, and Z.-R. Liu Phosphorylations of DEAD Box p68 RNA Helicase Are Associated with Cancer Development and Cell Proliferation Mol. Cancer Res., June 1, 2005; 3(6): 355 - 363. [Abstract] [Full Text] [PDF]

				M.-C. Etienne-Grimaldi, S. Pereira, N. Magne, J.-L. Formento, M. Francoual, X. Fontana, F. Demard, O. Dassonville, G. Poissonnet, J. Santini, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients Ann. Onc., June 1, 2005; 16(6): 934 - 941. [Abstract] [Full Text] [PDF]